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Asthma affects approximately 300 million people worldwide and is the most com-
mon chronic lung disease, which usually is associated with bronchial inflammation. 
Most research has focused upon the role of CD4+ T cells, and relatively few studies 
have addressed the phenotypic and functional roles of CD8+ T cell types and sub-
types. Human NK-like CD8+ T cells may involve cells that have been described as 
CD8+CD28−, CD8+CD28−CD57+, CD8+CD27−, or CD8+ effector memory (TEM) 
cells, among other. However, most of the data that are available regarding these various 
cell types were obtained in murine models did not thoroughly characterize these cells with 
phenotypically or functionally or did not involve asthma-related settings. Nevertheless, 
one may conceptualize three principal roles for human NK-like CD8+ T cells in asthma: 
disease-promoting, regulatory, and/or tissue repair. Although evidence for some of these 
roles is scarce, it is possible to extrapolate some data from overlapping or related CD8+ 
T cell phenotypes, with caution. Clearly, further research is warranted, namely in terms 
of thorough functional and phenotypic characterization of human NK-like CD8+ T cells 
in human asthma of varying severity.
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GeneRAL ASPeCTS ABOUT ASTHMA
Asthma affects approximately 300 million people worldwide and is the most common chronic lung 
disease (1). It is defined by a history of respiratory symptoms such as wheeze, shortness of breath, 
chest tightness, and cough that vary over time and in intensity, together with variable expiratory 
airflow limitation (2). In addition, it is a heterogeneous disease, usually characterized by chronic 
airway inflammation (2).
GeneRAL ASPeCTS ABOUT THe ROLe OF CD8+ T CeLLS  
in HUMAn ASTHMA
Although there are different clinical and cellular phenotypes in asthma, most research in terms of the 
role of T lymphocytes in this disease has been focused upon CD4+ T cells in the context of chronic 
airway inflammation. These CD4+ T cells produce various cytokines, namely IL-4, IL-9, and IL-13, 
that may contribute toward the underlying inflammation in asthma. In contrast, studies focusing on 
the role of CD8+ T cells in asthma have been comparatively scarce. Furthermore, most of the data 
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were obtained in murine models, and contradictory results have 
been produced by various groups, in terms of a possible role for 
these cells. In this context, possible pro-inflammatory, disease-
inducing roles versus protective or “regulatory” roles have been 
suggested by different studies, as recently reviewed by Baraldo 
et al. (3). It should be borne in mind that, in the various existing 
studies, CD8+ T cells were retrieved and characterized using 
different methodological approaches in terms of patient groups 
or murine models, biological samples, and study methods. These 
aspects may account for most of the discrepancies observed, 
which have indeed been clustering around a non-relevant role 
(4), a protective role (5), or a disease-favoring role, including 
association with poorer lung function (6–10) and possibly 
involving a significant direct and indirect contribution toward 
a Th2-high bronchial inflammation (11, 12). Nevertheless, it 
should also considered that different conditions of the local 
milieu in the target organ, possibly involving exposure to differ-
ent cytokines and/or antigen-producing cells may also explain 
discrepant results across existing studies. In addition, some 
experiments in murine models have also shown that the timing 
of the experimental setup with CD8+ T cells may also be very 
relevant in terms of the results observed. In this context, CD8+ T 
cells that produce high levels of IFN-gamma (Tc1 cells) have been 
shown to be associated with an attenuation of pulmonary allergic 
inflammation in rodent models. However, their role appears to 
depend upon their temporal relationship with the progression 
of allergic sensitization. In fact, depletion of CD8+ T cells prior 
to systemic OVA sensitization, either by blocking antibody 
directed against CD8+ or by using knockout mice, tends to be 
associated with attenuated allergic inflammation and bronchial 
hyperresponsiveness (BHR) in response to antigen challenge. 
However, administration of CD8+ blocking antibody after the 
initial allergen sensitization procedure results in further increase 
in BHR and eosinophilia (13).
Finally, it should be emphasized that many studies focusing 
on CD8+ cells in asthma have utilized different approaches to 
phenotypically characterizing these cells. In fact, in some cases, it 
is not clear whether the observed cells are classical CD8+ T cells, 
regulatory T cells, or NK-like CD8+ T cells.
GeneRAL ASPeCTS ABOUT THe ROLe 
OF HUMAn nK-LiKe CD8+ T CeLLS  
in ASTHMA
As far as we know, there are no published studies on human 
NK-like CD8+ T cells, as usually defined, in asthma. Human 
NK-like CD8+ T cells most likely comprise a whole array of cells 
with different phenotypes and functions, and further research is 
warranted in order to thoroughly clarify their ontogeny, patterns 
of differentiation, different phenotypes, and functions (Figure 1). 
In humans, NK-like T cells are a subset of CD8+ T cells that 
express prototypical NK cell markers, such as CD56, CD161, 
CD16, CD94, and CD57, with such expression increasing with 
aging. In most cases, these CD8+ T cells do not express CD28 
(14–16). For the sake of clarity, we will restrict our concept of 
human NK-like CD8+ T cells to CD8+ T lymphocytes that 
have been termed concurrently or independently CD28−CD8+ 
T cells, CD27−CD8+ T cells, CD28−CD57+CD8+ T cells, CD8+ 
effector memory T cells (TEM). A few data exist regarding these 
possible types of NK-like CD8+ T cells in humans, particularly 
in the setting of respiratory diseases such as asthma. In addition, 
given the fact that differences are apparent between these cells 
in mice and humans, we will only resort to information from 
murine models where strictly necessary.
CD8+CD28− T cells can be regarded as one of the pos-
sible subtypes of NK-like CD8+ T cells. There is a progressive 
oligoclonal accumulation of CD8+CD28− (and CD57+) T cells 
with natural aging, possibly due to multiple rounds of immune 
responses to antigenic exposures (17). In fact, chronic, persistent 
immune stimulation has been shown to be associated with recip-
rocal loss of CD28 expression and gain of CD57 expression on 
human, but not murine, CD8+ T cells (18, 19). Thus, most human 
CD8+CD28− T cells are CD57+, have shortened telomeres, rep-
resent late-differentiated T cells, and have been shown to express 
high levels of granzymes and perforin (20).
Various other phenotypic markers have been studied on 
CD8+CD28− T cells, namely CD27, and these phenotypes have 
been associated with different subtypes of memory T cells. It is 
generally accepted that human classical memory cells that have 
differentiated into an effector-like type (TEM) tend to be CD27− 
and CD28−, express perforin and granzymes, have moderate 
cytotoxic capacity but are capable of producing high levels of 
cytokines, namely IFN-gamma and TNF-alpha (21–23).
Can Human nK-Like CD8+ T Cells Have  
a Pro-inflammatory Role in Asthma?
In a study involving postmortem peribronchial region samples, 
the percentage of CD8+CD25+ T cells and perforin expression 
was higher in patients who had died from asthma (AD) than in 
asthmatic patients who had died of unrelated causes or in indi-
viduals who had died without a history of lung diseases (control 
groups) (6). In addition, the IFN-gamma/IL-4 ratio was lower in 
the AD than in the control groups.
Another study, involving asthmatic patients who were followed 
up for 14 years showed that the decline in lung function (FEV1), 
although mild, was clearly correlated with the number of CD8+ 
T-cells in airway biopsies, not just at baseline but also on follow-up 
(5). Curiously, a recent study in asthmatic patients demonstrated 
that the degree of airflow obstruction (FEV1 and FEF25–75) was 
correlated not with the total number of CD8+ T cells but rather 
with the number of CD8+ T-cells in the bronchoalveolar lavage 
fluid which expressed the high-affinity receptor for leukotriene 
B4 (BLT1) and produced IL-13 (10). Furthermore, the numbers 
of these cells also correlated with serum IgE levels and with the 
airway basement membrane thickness. However, CD8+ T cells 
were not further phenotyped in these studies, and we cannot 
know whether they also contained a subpopulation of NK-like 
CD8+ T cells.
Other studies have shown that CD8+CD28− (CD57+) T cells 
may be associated with inflammation in asthma, particularly in 
more severe cases. In this regard, the induced sputum of asthmatic 
patients was shown to contain more CD8+CD28− (CD57+) 
FiGURe 1 | Proposed roles for nK-like CD8+ T cells. In environments rich in IL-4, IL-6, IL-9, and low IFN-gamma, NK-like CD8+ T cells may acquire a 
pro-inflammatory role with expression of BLT1 and production of perforin, IL-5, IL-9, and IL-13. In environments rich in IL-4 and IL-12 or IL-15, NK-like CD8+ T cells 
may differentiate into regulatory T cells, with production of IFN-gamma, TGF-beta, and IL-10. In pro-inflammatory contexts, rich in IL-18 and IL-33, NK-like CD8+  
T cells may produce amphiregulin, thereby promoting tissue regeneration.
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T  cells than CD8+CD28+ T cells, in contrast to what was 
observed in healthy controls. Furthermore, these CD8+CD28− T 
cells were also shown to be more abundant and to contain lower 
levels of IFN-gamma in severe asthmatics than in mild asthmatics 
and age-matched healthy controls. Furthermore, CD8+CD28− 
(CD57+) T cells from severe asthmatics expressed high levels 
of intracytoplasmic perforin and demonstrated a clearly more 
potent cytotoxic activity than in CD8+CD28− T cells from 
healthy controls and mild asthmatics (24). To what extent this 
increased cytotoxic activity is relevant to inflammation in asthma 
still needs to be ascertained.
Clearly, further studies are needed, particularly in terms of 
the cytokines produced by these CD8+CD28− T cells in asthma. 
A lower production of IFN-gamma in asthma may be relevant in 
that it may be less effective at counterbalancing Th2-associated 
cytokines. In this regard, it should be stressed that, just like CD4+ 
T cells, CD8+ T cells can also be subdivided into T1-type (Tc1) 
and T2-types (Tc2), on the basis of the cytokines they produce 
(25, 26). Thus, some CD8+ T cells produce high levels of IL-4 
and/or IL-13, possibly under the influence of IL-4 produced by 
Th2-type CD4+ T cells, as was shown in a murine model (27). 
The relevance of IL-4 produced by these CD8+ T cells is not clear, 
but it may contribute toward tissue remodeling (28). This is even 
more relevant since IL-4 production has been demonstrated in 
peripheral blood CD8+ T cells from patients with atopic asthma 
(29). More importantly, IL-13 may also significantly contribute 
toward bronchial inflammation, airway hyperresponsiveness, 
mucus hypersecretion, and tissue remodeling as has been shown 
in murine models and models of human bronchial epithelium 
(28, 30, 31).
In addition, a subset of effector memory (TEM) CD8+ T cells 
with high levels of IL-6Ra expression in human peripheral blood 
was reported. IL-6Ralphahigh EM CD8+ T cells actively prolifer-
ated, survived, and produced high levels of IL-5 and IL-13. Also, 
patients with asthma had an increased frequency of IL-6Ralphhigh 
CD8+ T cells (TEM) in peripheral blood compared with healthy 
control subjects. It is possible that these cells may serve as a pool, 
which expands with immune stimulation (32).
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Finally, CD8+ T cells may also produce other cytokines that 
are very relevant to the pathophysiology of bronchial asthma, 
such as IL-9 (Tc9 cells) and IL-17 (Tc17 cells), which may have 
a role even in Th2-low settings (11, 33). In fact, a recent study 
showed that the numbers of peripheral blood Tc2 and Tc17 cells 
were increased in asthmatic versus non-asthmatic individuals 
(33). Again, production of these cytokines should be analyzed in 
human NK-like CD8+ T cells.
Can Human nK-Like CD8+ T Cells Have  
a Regulatory Function in Asthma?
In the case of CD8+ T cells, two of the possible ways these cells 
might have a regulatory function in asthma would be via high 
production of IFN-gamma and/or via mechanisms generally 
associated with “regulatory” T cells and involving the produc-
tion of IL-10 or TGF-beta or direct cell-cell contact-associated 
suppression.
Increased expression of IFN-gamma producing CD8+ T cells 
has been demonstrated in subjects with asthma (12, 34), although 
a decreased expression of IFN-gamma in CD8+ T cells in atopic 
asthmatic patients has also been described (35) and CD8+ T cells 
from atopic asthmatic subjects have been shown to contain more 
IL-4 than those from non-atopic donors (29). In fact, memory 
CD8+ T cells can be activated in the presence or absence of 
specific antigen expressed by dendritic cells, in association with 
the pro-inflammatory cytokines IL-15 and IL-18, to produce 
IFN-gamma that leads to the suppression of the underlying Th2-
driven allergic airway inflammation (36).
In fact, in the presence of IL-4 and IL-12, murine CD8+ 
T cells have been shown to become CD39+ Foxp3-negative 
“regulatory” T cells that demonstrate suppressive activity via 
production of IL-10 and contact-dependent mechanisms (5). 
Furthermore, memory CD8+ T cells present in the airways of 
mice after an influenza infection have been shown to suppress 
the development of subsequent Th2-driven allergic inflammation 
in an IFN-gamma dependent way (37). In addition, the adoptive 
transfer of IFN-gamma-producing CD8+ T cells directly into the 
airways suppressed the allergic response in pre-sensitized mice 
(36). However, to what extent these CD8+ Tregs are CD28− has 
not been described.
It is thought that naïve CD8+CD25+ cells can differentiate 
into CD8+ Tregs in the presence of antigen and the relevant 
cytokines (38). As an example, human CD8+ Treg can be 
generated in the presence of IL-4 and IL-12; these cells are 
CD25+Foxp3+ and are capable of secreting IL-10, TNF-alpha, 
IFN-gamma as well as granzymes (39). Furthermore, these cells 
have been shown to block the activation of naïve or effector T 
cells, to suppress IgG/IgE antibody responses (39), IL-4 expres-
sion, and the proliferation of CD4+ T cells (40). However, most 
of these cells described in humans are CD28+ (39–41) and 
most likely do not involve NK-like CD8+ T cells. An alternative 
pathway in terms of CD8+ T cell differentiation toward Tregs 
may involve IL-15. In this context, human CD8+CD56− T cells, 
stimulated with IL-15, were shown to acquire the capacity to 
secrete IFN-gamma, IL-1beta, TGF-beta, and IL-10, suggesting 
a regulatory phenotype (42).
It should be stressed that a subset of human CD8+CD28− T 
suppressor cells, which were shown to act upon antigen-presenting 
cells, rendering them tolerogenic to CD4+ T cells were described 
in a model of mixed lymphocyte reaction (43). Phenotypic analy-
ses of these CD8+CD28− T cells showed that they were CD3+, 
CD5high, CD8high, CD27+, CD56−, CD62L+ (44) opening up the 
possibility of the existence of CD8+CD28− Tregs in humans.
In human asthma, flow cytometry analysis showed an increased 
percentage of CD8+CD28− T cells in peripheral blood of adult 
allergic asthmatics compared to controls (45). In addition, patients 
with severe asthma had a higher percentage of CD8+CD28− and 
CD8+CD28−TCRalpha/beta+CD62Lhigh FoxP3bright T cells than 
the other groups after enrichment, suggesting that these cells 
might not be immunosuppressive or that their increased numbers 
in asthma might indicate a tissue damage-limiting function, as 
happens in the context of viral infections [reviewed by Josefowicz 
et  al. (46)]. In contrast, the same group of researchers showed 
that the percentages of peripheral blood CD8+CD25+FoxP3bright 
T cells of patients with severe asthma or mild to moderate asthma 
were markedly lower than those of non-asthmatic controls (47). 
Curiously, the percentages of CD8+CD25+FoxP3bright T cells cor-
related with mean peak expiratory flow (PEF%) values in these 
asthmatic patients (47). Although this study did not analyze 
whether these CD8+ Tregs were CD28− (and/or CD57+), joint 
analysis of the results from the studies by these researchers may 
suggest that the CD8+CD28− described in their reports are not 
true immunosuppressive Tregs, which is in line with results from 
various other groups that have described CD8+CD28− T cells 
as essentially cytotoxic and not immunosuppressive (24, 48–51). 
Furthermore, other authors have also shown that human 
CD8+CD57+ T cells are mostly cytotoxic, at least those that are 
present in the context of autoimmune diseases (52–56).
Nevertheless, the picture is not clear at all, since a clear 
immunosuppressive activity carried out by CD8+CD57+ T cells 
(57–59) as well as by CD8+CD28− T cells (44, 60–63) has been 
described, but in the context of tissue transplantation and auto-
immune diseases in humans. To what extent this may apply to 
allergy and asthma needs to be determined.
Thus, in order to clarify this issue of human NK-like 
(CD8+CD28−) T cells having or not “regulatory” properties 
in human asthma, further studies are needed, involving a 
thorough phenotypic and functional characterization of both 
peripheral blood and bronchial CD8+CD28−CD57+ as well as 
CD8+CD28−CD57− T cells in patients with bronchial asthma of 
different degrees of severity as well as in non-asthmatic controls.
Can Human nK-Like CD8+ T Cells Have a 
Tissue-Regenerating Function in Asthma?
Amphiregulin is an epidermal growth factor ligand, which 
apparently promotes tissue repair under inflammatory condi-
tions [reviewed by Berasain and Avila (64)]. Studies in a murine 
model have shown that, through the production of amphiregulin, 
Treg cells have a direct role in lung tissue repair and maintenance 
during viral infection that is independent of their suppressive 
activity and is induced by different stimuli (65). In this context, 
the pro-inflammatory cytokine IL-18 and the alarmin IL-33, 
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which are upregulated in the context of inflammation and  tissue 
damage, induced in  vitro amphiregulin production by Treg, 
independently of TCR stimulation. However, this study did not 
fully clarify which type of Tregs was involved, although mostly 
CD4+ Tregs were studied.
Amphiregulin is also produced by human T cells, as shown 
in a study in which signaling through the TCR induced 
amphiregulin expression by most or all human T cell subsets in 
peripheral blood, including naive and memory CD4+ and CD8+ 
T cells, Th1 and Th2 in vitro T cell lines, and subsets of memory 
CD4+ T cells (66). In these different T cell types, amphiregulin 
synthesis was regulated essentially by acute signals, which may 
be appropriate for tissue repair. Importantly, amphiregulin-
producing CD4+Foxp3+ Tregs have been described in damaged 
tissues, namely muscles in murine models (67). Furthermore, the 
specialized proresolving mediator maresin-1 has been shown to 
reduce asthma-associated bronchial inflammation in a murine 
model, and this was associated with an increased expression 
of amphiregulin and de novo generation of CD4+ Tregs (68). 
It is, thus, possible that damaged bronchial tissue in cases of 
severe asthma may be associated with the local accumulation of 
amphiregulin-producing Treg. However, amphiregulin expres-
sion has not been studied in human NK-like, CD8+CD28− 
T cells. In addition, amphiregulin expression in asthma must be 
interpreted with caution, since elevated levels of amphiregulin 
have been detected in induced sputum in asthmatic children, 
where its levels correlated with the numbers of sputum eosino-
phils and sputum eosinophil cationic protein (69). Furthermore, 
there was a significant negative correlation between sputum 
amphiregulin and lung function (FEV1). Finally, another study 
in asthmatic children showed that levels of amphiregulin in the 
sputum were increased in disease exacerbations (47). In addition, 
in this study, amphiregulin was also shown to induce prolifera-
tion of normal human bronchial epithelial cells, which may be 
associated with tissue remodeling in asthma.
COnCLUSiOn
Independently of other reasons, seemingly contradictory 
findings regarding human CD8+ T cells, namely NK-like CD8+ 
T cells may be due to different populations/subpopulations 
involved in the different experimental setups used. In addition, 
a clearer definition of the CD8+ subsets both in phenotypic and 
functional terms would allow more useful comparisons between 
studies both in animal models (rodent) and in human pathologi-
cal contexts.
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